Invention Grant
US09540698B2 MIR-193A-3P and associated genes predict tumorigenesis and chemotherapy outcomes
有权
MIR-193A-3P和相关基因预测肿瘤发生和化疗结果
- Patent Title: MIR-193A-3P and associated genes predict tumorigenesis and chemotherapy outcomes
- Patent Title (中): MIR-193A-3P和相关基因预测肿瘤发生和化疗结果
-
Application No.: US14807647Application Date: 2015-07-23
-
Publication No.: US09540698B2Publication Date: 2017-01-10
- Inventor: Jingde Zhu
- Applicant: Genedia Biotech Co., Ltd.
- Applicant Address: CN Kunshan, Jiangsu
- Assignee: Genedia Biotech Co., Ltd.
- Current Assignee: Genedia Biotech Co., Ltd.
- Current Assignee Address: CN Kunshan, Jiangsu
- Agency: Sheppard Mullin Richter & Hampton LLP
- Main IPC: G01N33/574
- IPC: G01N33/574 ; C12Q1/68
Abstract:
The disclosure provides a correlation between the expression level of the miR-193a gene, which can be regulated by its methylation status, and both tumorigenesis of and the resistance of a cancer cell to a pyrimidine antimetabolite (5-FU) based chemotherapy. In addition to the methylation status and the expression of miR-193a, its downstream genes, such as E2F1, SRSF2, and apoptotic genes such as caspase 2, are also involved and can serve as useful markers for cancer therapy prognosis and for therapy selection.
Public/Granted literature
- US20160017437A1 MIR-193A-3P AND ASSOCIATED GENES PREDICT TUMORIGENESIS AND CHEMOTHERAPY OUTCOMES Public/Granted day:2016-01-21
Information query
IPC分类:
